Home > Products > All > NELARABINE Injection*
Product Image
Please see full prescribing and safety information, including boxed warning, for NELARABINE single-dose vials.

Available in:

  • 250 mg per 50 mL single-dose vials

Benefits:

  • AP Rated
  • Preservative-free
  • Not made with natural rubber latex

Downloads:

PreventIV

NELARABINE Injection*

Brand Name Equivalent: ARRANON® (ARRANON is a registered trademark of Sandoz AG Corp.)
Therapeutic Category: Oncology

PreventIV Measures® Features:

  • Easy-to-read drug name and dosage strength to aid in identifying the right product
  • Bar codes included on the vial and carton for ease of scanning
  • Unique label design to help products stand out on the shelf
  • Enhanced packaging and labeling designed to promote safety and help reduce the risk of medication errors
NDC
#25021		 Description Strength Fill
Volume 		Concentration Container
Size 		Closure Unit
of Sale
259-50 Glass Vial 250 mg 50 mL 5 mg per mL 50 mL 20 mm 1
259-51 Glass Vial 250 mg 50 mL 5 mg per mL 50 mL 20 mm 6
WARNING: NEUROLOGIC ADVERSE REACTIONS Severe neurologic adverse reactions have been reported with the use of nelarabine. These adverse reactions have included altered mental states including severe somnolence, central nervous system effects including convulsions, and peripheral neuropathy ranging from numbness and paresthesias to motor weakness and paralysis. There have also been reports of adverse reactions associated with demyelination and ascending peripheral neuropathies similar in appearance to Guillain-Barré syndrome. Full recovery from these adverse reactions has not always occurred with cessation of therapy with nelarabine. Monitor frequently for signs and symptoms of neurologic toxicity. Discontinue nelarabine for neurologic adverse reactions of NCI Common Toxicity Criteria for Adverse Events (CTCAE) Grade 2 or greater.